ZNF154 and neoplasm: Using the same stratification criteria described above but applied to a cohort of 492 LUAD patients, we found that patients whose primary tumours expressed higher ZNF154 levels (n = 123, 25% of cohort) also had significantly better overall survival compared to the remaining patient cohort (Fig. 2C, Log-rank, p < 0.05).